NCT04554069

Brief Summary

Assessment of the influence of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
280

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 5, 2020

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 18, 2020

Completed
9 months until next milestone

Study Start

First participant enrolled

June 1, 2021

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2022

Completed
Last Updated

January 22, 2021

Status Verified

January 1, 2021

Enrollment Period

7 months

First QC Date

September 5, 2020

Last Update Submit

January 21, 2021

Conditions

Hypertension

Outcome Measures

Primary Outcomes (1)

  • The effect of different antihypertensive drugs on serum uric acid in newly diagnosed hypertension.

    we will measure the change of the level of serum uric acid after 6 months from the treatment of antihypertensive durgs

    6 months from baseline

Secondary Outcomes (1)

  • obesity

    6 months from baseline

Eligibility Criteria

Age30 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Male and Female participants aged 30 years old and above will be invited to participate in this study.

You may qualify if:

  • All newly diagnosed hypertensive patients aged 30 years old and above will be invited to participate in this study

You may not qualify if:

  • Patients below 30 years old.
  • Patients with kidney disease.
  • Patients who are taking medications known to increase SUA as (Thiazide and Loop diuretics, Salicylates, Cyclosporin use) or decrease the level of uric acid in the urine as (Allopurinol, Febuoxstate).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000 Dec;36(6):1072-8. doi: 10.1161/01.hyp.36.6.1072.

    PMID: 11116127BACKGROUND

  • Shankar A, Klein R, Klein BE, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens. 2006 Dec;20(12):937-45. doi: 10.1038/sj.jhh.1002095. Epub 2006 Oct 5.

    PMID: 17024135BACKGROUND

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Dalia Mahran, Professor

    faculty of medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mentallah Abdelrahman, MBBCH

CONTACT

+201092772639menahallah.osama@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Public Health and Community Medicine

Study Record Dates

First Submitted

September 5, 2020

First Posted

September 18, 2020

Study Start

June 1, 2021

Primary Completion

January 1, 2022

Study Completion

February 1, 2022

Last Updated

January 22, 2021

Record last verified: 2021-01